We identified druggable fusions, particularly CEP85L‐ROS1 and GOPC‐ROS1, that bound crizotinib analogues (e.g., entrectinib and larotrectinib) in TCGA GBM patients, as reported previously by Davare et al. Here, CEP85L is linked to glioblastoma.